AU2007264682B2 - Method of treatment of age-related macular degeneration - Google Patents

Method of treatment of age-related macular degeneration Download PDF

Info

Publication number
AU2007264682B2
AU2007264682B2 AU2007264682A AU2007264682A AU2007264682B2 AU 2007264682 B2 AU2007264682 B2 AU 2007264682B2 AU 2007264682 A AU2007264682 A AU 2007264682A AU 2007264682 A AU2007264682 A AU 2007264682A AU 2007264682 B2 AU2007264682 B2 AU 2007264682B2
Authority
AU
Australia
Prior art keywords
cells
microglia
mice
cop
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007264682A
Other languages
English (en)
Other versions
AU2007264682A1 (en
Inventor
Oleg Butovsky
Michal Eisenbach-Schwartz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of AU2007264682A1 publication Critical patent/AU2007264682A1/en
Application granted granted Critical
Publication of AU2007264682B2 publication Critical patent/AU2007264682B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
AU2007264682A 2006-06-28 2007-06-28 Method of treatment of age-related macular degeneration Ceased AU2007264682B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80604106P 2006-06-28 2006-06-28
US60/806,041 2006-06-28
PCT/IL2007/000798 WO2008001380A2 (en) 2006-06-28 2007-06-28 Method of treatment of age-related macular degeneration

Publications (2)

Publication Number Publication Date
AU2007264682A1 AU2007264682A1 (en) 2008-01-03
AU2007264682B2 true AU2007264682B2 (en) 2012-09-06

Family

ID=38846104

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007264682A Ceased AU2007264682B2 (en) 2006-06-28 2007-06-28 Method of treatment of age-related macular degeneration

Country Status (7)

Country Link
US (1) US9089509B2 (enExample)
EP (1) EP2046366B1 (enExample)
JP (1) JP5412280B2 (enExample)
AU (1) AU2007264682B2 (enExample)
CA (1) CA2656463C (enExample)
ES (1) ES2605154T3 (enExample)
WO (1) WO2008001380A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008075365A1 (en) * 2006-12-20 2008-06-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods for treatment of age related degeneration of the retina
JP2012518407A (ja) * 2009-02-20 2012-08-16 ザ スクリプス リサーチ インスティチュート 単離された単球集団及び関連した治療応用
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
WO2012143924A1 (en) 2011-04-21 2012-10-26 Mapi Pharma Ltd. Random pentapolymer for treatment of autoimmune diseases
US20130217986A1 (en) * 2012-02-21 2013-08-22 Ucl Business Plc Method and system for predicting an amyloidosis status
WO2016183585A1 (en) * 2015-05-14 2016-11-17 Joslin Diabetes Center, Inc. Retinol-binding protein 3 (rbp3) as a protective factor in non-diabetic retinal degeneration
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
HRP20250396T1 (hr) 2016-08-31 2025-05-23 Mapi Pharma Ltd. Depo sustavi koji sadrže glatiramer acetat
PL3565823T3 (pl) * 2017-01-04 2024-10-28 Worg Pharmaceuticals (Zhejiang) Co., Ltd. Peptydy S-arestyn oraz ich zastosowanie terapeutyczne
AU2018242998B2 (en) 2017-03-26 2023-11-02 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030004099A1 (en) * 2000-01-20 2003-01-02 Eisenbach-Schwartz Michael The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
US20040092435A1 (en) * 2002-11-07 2004-05-13 Peyman Gholam A. Treatment of ocular disease
WO2004060265A2 (en) * 2003-01-07 2004-07-22 Yeda Research And Development Co. Ltd. Eye-drop vaccine containing copolymer 1 for therapeutic immunization
US20040248802A1 (en) * 2001-06-28 2004-12-09 Yeda Research And Development Co. Ltd. Poly-Glu, Tyr for neuroprotective therapy
US20050118180A1 (en) * 1999-10-15 2005-06-02 Joseph Rubinfeld Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
US20050220803A1 (en) * 2002-03-26 2005-10-06 Yeda Research And Development Co. Ltd. Use of an organ-specific self-pathogen for treatment of a non-autoimmune disease of said organ
US20060057110A1 (en) * 2002-06-14 2006-03-16 Yeda Research And Development Co. Ltd. Antigen-presenting cells for neuroprotection and nerve regeneration

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
JP2003521448A (ja) 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
WO2000005250A1 (en) 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
US20030149997A1 (en) * 1999-02-19 2003-08-07 Hageman Gregory S. Diagnostics and therapeutics for arterial wall disruptive disorders
US6524012B1 (en) * 2001-09-06 2003-02-25 Gkn Automotive, Inc. Securing members together by spring rings
EP1476583B1 (en) * 2002-01-25 2013-08-28 Biomedical Design, Inc. Calcification-resistant fixation
US7860975B2 (en) * 2002-07-31 2010-12-28 Oracle America, Inc. System and method for secure sticky routing of requests within a server farm

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050118180A1 (en) * 1999-10-15 2005-06-02 Joseph Rubinfeld Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
US20030004099A1 (en) * 2000-01-20 2003-01-02 Eisenbach-Schwartz Michael The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
US20040248802A1 (en) * 2001-06-28 2004-12-09 Yeda Research And Development Co. Ltd. Poly-Glu, Tyr for neuroprotective therapy
US20050220803A1 (en) * 2002-03-26 2005-10-06 Yeda Research And Development Co. Ltd. Use of an organ-specific self-pathogen for treatment of a non-autoimmune disease of said organ
US20060057110A1 (en) * 2002-06-14 2006-03-16 Yeda Research And Development Co. Ltd. Antigen-presenting cells for neuroprotection and nerve regeneration
US20040092435A1 (en) * 2002-11-07 2004-05-13 Peyman Gholam A. Treatment of ocular disease
WO2004060265A2 (en) * 2003-01-07 2004-07-22 Yeda Research And Development Co. Ltd. Eye-drop vaccine containing copolymer 1 for therapeutic immunization

Also Published As

Publication number Publication date
EP2046366B1 (en) 2016-08-31
WO2008001380A3 (en) 2009-04-30
ES2605154T3 (es) 2017-03-13
CA2656463C (en) 2015-12-01
AU2007264682A1 (en) 2008-01-03
EP2046366A2 (en) 2009-04-15
US9089509B2 (en) 2015-07-28
JP5412280B2 (ja) 2014-02-12
EP2046366A4 (en) 2011-09-21
JP2009542622A (ja) 2009-12-03
US20100135953A1 (en) 2010-06-03
CA2656463A1 (en) 2008-01-03
WO2008001380A2 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
AU2007264682B2 (en) Method of treatment of age-related macular degeneration
US20120135016A1 (en) Induction of neurogenesis and stem cell therapy in combination with copolymer 1
Weber et al. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis
CN100438906C (zh) 共聚物1和相关肽和多肽及其处理过的t细胞在保护cns细胞避免谷氨酸毒性中的用途
US9517256B2 (en) Vaccine and method for treatment of neurodegenerative diseases
Kala et al. Recent insights into the mechanism of action of glatiramer acetate
AU2002345323B2 (en) Use of poly-Glu, Tyr for neuroprotective therapy
EP0482089B1 (en) Method of treating autoimmune uveoretinitis in human
Schwartz Harnessing the immune system for neuroprotection: therapeutic vaccines for acute and chronic neurodegenerative disorders
JP6474082B2 (ja) 眼疾患および眼障害の治療のためのヒト単球亜集団
WO2006056998A2 (en) Methods of cell therapy, neurogenesis and oligodendrogenesis
HK1127858B (en) Copolymer-1 for treatment of age-related macular degeneration
Schwartz Immune-Based Cell Therapy for Acute and Chronic Neurodegeneratlve Disorders
Benson Efficacy and mechanisms of oral tolerance to myelin basic protein in relapsing experimental autoimmune encephalomyelitis
IL159535A (en) USE OF POLY-Glu50, Tyr50 FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR NEUROPROTECTION THERAPY

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired